Program
Tamsulosin
Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.
Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 140 open or running | phase 4since Sep 18, 2014 | Jun 19, 2006 | none ahead |
| Astellas Pharma | 100 open or running | phase 4since Mar 17, 2016 | Jul 25, 2007 | none ahead |
| GlaxoSmithKline | 90 open or running | phase 4since Feb 10, 2011 | Aug 24, 2004 | none ahead |
| Hanmi Pharmaceutical | 50 open or running | phase 3since Feb 23, 2015 | Sep 4, 2014 | none ahead |
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Menarini Group | 33 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| GL Pharm Tech | 20 open or running | phase 3since Nov 11, 2014 | Feb 24, 2014 | none ahead |
| Jeil Pharmaceutical | 20 open or running | phase 3since Nov 21, 2016 | Jul 1, 2014 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jun 22, 2010 | Jun 22, 2010 | none ahead |
| adium | 10 open or running | no phasesince Jul 7, 2026 | Jul 7, 2026 | none ahead |
| ascension-health | 10 open or running | phase 4since Nov 5, 2016 | Nov 5, 2016 | none ahead |
| Dexa Medica Group | 10 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| getz-pharma | 10 open or running | phase 4since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| IlDong Pharmaceutical | 10 open or running | phase 3since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| neotract-inc | 11 open or running | phase 4since Jul 9, 2021 | Jul 9, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Aug 24, 2004.
- Oct 1, 2015Phase 3 study in Urological ManifestationsBoehringer Ingelheim · NCT02573311 · 1,117 enrolled · United States
- Dec 16, 2015Phase 1 study in Prostatic HyperplasiaAstellas Pharma · NCT02634489 · 46 enrolled · Netherlands
- Jan 29, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02715401 · 36 enrolled
- Feb 24, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02712411 · 30 enrolled · Korea, Republic of
- Mar 17, 2016Phase 4 study in Lower Urinary Tract SymptomsAstellas Pharma · NCT02715024 · 52 enrolled · Taiwan
- Jul 22, 2016IlDong Pharmaceutical's first study: phase 3 study in Prostatic HyperplasiaNew to IlDong PharmaceuticalIlDong Pharmaceutical · NCT02862483 · 330 enrolled · Korea, Republic of
- Nov 5, 2016ascension-health's first study: phase 4 study in Postoperative Urinary RetentionNew to ascension-healthascension-health · NCT02958878 · 210 enrolled
- Nov 21, 2016Phase 3 study in Lower Urinary Tract SymptomsJeil Pharmaceutical · NCT02972268 · 780 enrolled · Korea, Republic of
- Jul 9, 2021neotract-inc's first study: phase 4 study in BPHNew to neotract-incneotract-inc · NCT04987892 · 250 planned · United States
- Jul 7, 2023getz-pharma's first study: phase 4 study in Ureteric Stone of Lower Third of UreterNew to getz-pharmagetz-pharma · NCT05977647 · 240 enrolled · Pakistan
- Aug 14, 2024Dexa Medica Group's first study: phase 1 study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT06558032 · 28 enrolled · Indonesia
- Jul 22, 2025Menarini Group's first study: phase 1 study in Healthy VolunteersNew to Menarini GroupMenarini Group · NCT07091669 · 46 enrolled · Armenia
- Aug 21, 20252 phase 1 studiesMenarini Group · NCT07146711, NCT07156916
- Jul 7, 2026adium's first study: no phase study in BioequivalenceNew to adiumadium · NCT07698288 · 66 enrolled · Mexico
TargetBeta
“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 56 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07698288Bioequivalence · Mexico | – | Completed | adium | Apr 16, 2026 | 66 |
| NCT07156916Healthy Volunteer Male Subjects · Armenia | 1 | Recruiting | Menarini Group | Mar 1, 2026 | 46 |
| NCT07146711Healthy Adult Males Volunteers · Armenia | 1 | Active, not recruiting | Menarini Group | Oct 1, 2025 | 33 |
| NCT07091669Healthy Volunteers · Armenia | 1 | Active, not recruiting | Menarini Group | Aug 1, 2025 | 46 |
| NCT06558032Healthy · Indonesia | 1 | Completed | Dexa Medica Group | Dec 16, 2023 | 28 |
| NCT05977647Ureteric Stone of Lower Third of Ureter · Pakistan | 4 | Completed | getz-pharma | May 30, 2025 | 240 |
| NCT04987892BPH · United States | 4 | Recruiting | neotract-inc | May 2025 | 250 |
| NCT02972268Lower Urinary Tract Symptoms · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Nov 2, 2017 | 780 |
| NCT02958878Postoperative Urinary Retention | 4 | Completed | ascension-health | Nov 30, 2018 | 210 |
| NCT02862483Prostatic Hyperplasia · Korea, Republic of | 3 | UNKNOWN | IlDong Pharmaceutical | Mar 2017 | 330 |
| NCT02715024Lower Urinary Tract Symptoms · Taiwan | 4 | Completed | Astellas Pharma | Apr 2011 | 52 |
| NCT02712411Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Aug 2015 | 30 |
| NCT02715401Erectile Dysfunction | 1 | Completed | Hanmi Pharmaceutical | Nov 2015 | 36 |
| NCT02634489Prostatic Hyperplasia · Netherlands | 1 | Completed | Astellas Pharma | Jul 2009 | 46 |
| NCT02573311Urological Manifestations · United States | 3 | Completed | Boehringer Ingelheim | Aug 1, 2016 | 1,117 |
| NCT03246880Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 455 |
| NCT02529800Healthy | 1 | Completed | Hanmi Pharmaceutical | Oct 2015 | 24 |
| NCT02417844Prostatic Hyperplasia | 1 | Completed | Boehringer Ingelheim | May 2015 | 34 |
| NCT02390882Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | May 2015 | 494 |
| NCT02303769Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | GL Pharm Tech | May 2015 | 309 |
| NCT02266537Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2006 | 97 |
| NCT02266524Urination Disorders | 1 | Completed | Boehringer Ingelheim | Apr 2005 | 48 |
| NCT02266511Healthy | 1 | Completed | Boehringer Ingelheim | Sep 1999 | 30 |
| NCT02264184Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 24 |
| NCT02244294Prostatic Hyperplasia | 2 | Completed | Boehringer Ingelheim | Jun 2005 | 176 |
| NCT02244281Lower Urinary Tract Symptoms | 2 | Completed | Boehringer Ingelheim | Nov 2003 | 74 |
| NCT02244255Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Jun 2000 | 1,993 |
| NCT02244242Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Aug 1999 | 493 |
| NCT02244229Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Nov 2000 | 403 |
| NCT02247518Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 16 |
| NCT02247505Healty Male Volunteers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 29 |
| NCT02239484Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 30 |
| NCT02180997Prostatic Hyperplasia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 36 |
| NCT02169713Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Aug 2014 | 20 |
| NCT02138773Healthy · China | 1 | Completed | Astellas Pharma | Jul 2014 | 80 |
| NCT02072213Healthy · Korea, Republic of | 1 | Completed | GL Pharm Tech | Jan 2014 | 36 |
| NCT02058576Urologic Diseases · United Kingdom | 1 | Completed | GlaxoSmithKline | Jan 2, 2015 | 77 |
| NCT02052713Urologic Diseases · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 29, 2014 | 78 |
| NCT02058368Prostatic Hyperplasia · China, Japan, Korea, Republic of and more | 3 | Completed | GlaxoSmithKline | Mar 3, 2017 | 607 |
| NCT01957189Prostatic Hyperplasia · China | 1 | Completed | GlaxoSmithKline | Jan 22, 2014 | 24 |
| NCT01953887EC905 · United Kingdom | 1 | Completed | Astellas Pharma | Jul 2010 | 30 |
| NCT01777269Prostatic Hyperplasia · Australia, France, Germany and more | 4 | Completed | GlaxoSmithKline | Apr 5, 2016 | 489 |
| NCT01726270Lower Urinary Tract Symptoms · United States | 2 | Completed | Boehringer Ingelheim | Mar 2013 | 689 |
| NCT01657851Prostatic Hyperplasia · Russian Federation | 1 | Completed | GlaxoSmithKline | Dec 5, 2012 | 35 |
| NCT01673490Prostatic Hyperplasia · Vietnam | 4 | Terminated | GlaxoSmithKline | Mar 20, 2015 | 59 |
| NCT01489696Cardiovascular · United Kingdom | 1 | Completed | Astellas Pharma | Feb 2011 | 48 |
| NCT01294592Prostatic Hyperplasia · France, Germany, Greece and more | 4 | Completed | GlaxoSmithKline | Oct 17, 2013 | 742 |
| NCT01149746Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Dec 2004 | 32 |
| NCT01149733Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2004 | 32 |
| NCT01021332Lower Urinary Tract Symptoms · Austria, Belarus, Belgium and more | 3 | Completed | Astellas Pharma | Dec 14, 2011 | 1,067 |
| NCT01018511Prostatic Hyperplasia · Austria, Belarus, Belgium and more | 3 | Completed | Astellas Pharma | Mar 1, 2011 | 1,334 |
| NCT00796614Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 3 | Completed | Boehringer Ingelheim | Feb 2009 | 231 |
| NCT00510406Lower Urinary Tract Symptoms · Austria, Czech Republic, Denmark and more | 2 | Completed | Astellas Pharma | Sep 2007 | 919 |
| NCT00507455Lower Urinary Tract Symptoms · United States, Belgium, Czech Republic and more | 2 | Completed | Astellas Pharma | Aug 2008 | 222 |
| NCT00340704Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 2 | Completed | Boehringer Ingelheim | Jun 2009 | 143 |
| NCT00090103Prostatic Hyperplasia · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2009 | 4,844 |
How it is read
Names in the registry
- “Tamsulosin”, 12 entries
- “tamsulosin hydrochloride”, 6 entries
- “Tamsulosin (0.4 mg/j)”, 5 entries
- “tamsulosin”, 4 entries
- “HIP1402”, 3 entries
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 22 studies
- Lower Urinary Tract Symptoms, 6 studies
- Erectile Dysfunction, 3 studies
- Urologic Diseases, 2 studies
- Urinary Bladder, Neurogenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.